34.06
-0.89 (-2.55%)
| Previous Close | 34.95 |
| Open | 34.83 |
| Volume | 191,266 |
| Avg. Volume (3M) | 796,870 |
| Market Cap | 1,942,486,144 |
| Price / Earnings (TTM) | 16.14 |
| Price / Earnings (Forward) | 8.84 |
| Price / Sales | 2.97 |
| Price / Book | 3.34 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | 17.98% |
| Operating Margin (TTM) | 33.17% |
| Diluted EPS (TTM) | 2.11 |
| Quarterly Revenue Growth (YOY) | 16.10% |
| Quarterly Earnings Growth (YOY) | 19.80% |
| Total Debt/Equity (MRQ) | 31.04% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | 220.92 M |
| Levered Free Cash Flow (TTM) | 168.65 M |
| Return on Assets (TTM) | 12.85% |
| Return on Equity (TTM) | 22.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Harmony Biosciences Holdings, I | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.62% |
| % Held by Institutions | 93.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Valor Management Llc | 30 Sep 2024 | 11,218,033 |
| Venbio Partners Llc | 30 Sep 2024 | 614,594 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 75.00 (HC Wainwright & Co., 120.20%) | Buy |
| Median | 55.00 (61.48%) | |
| Low | 40.00 (Raymond James, 17.44%) | Buy |
| Average | 56.00 (64.42%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 34.11 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Dec 2024 | 75.00 (120.20%) | Buy | 33.63 |
| Cantor Fitzgerald | 30 Oct 2024 | 58.00 (70.29%) | Buy | 33.80 |
| Needham | 30 Oct 2024 | 52.00 (52.67%) | Buy | 33.80 |
| 29 Oct 2024 | 52.00 (52.67%) | Buy | 41.49 | |
| Oppenheimer | 30 Oct 2024 | 59.00 (73.22%) | Buy | 33.80 |
| Mizuho | 10 Oct 2024 | 52.00 (52.67%) | Buy | 34.81 |
| Raymond James | 10 Oct 2024 | 40.00 (17.44%) | Buy | 34.81 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |